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Fig. 3. Time-dependent induction (P < 0.05; Anova) of 
pancreatic islet and liver glucokinase (0) (mU/mg protein) 
by glibenclamide treatment (once 4 hours, twice daily for 
1 day and twice daily for 2 days 0.4 mg/kg body weight S.C. 
before measurement) in four-day starved rats. Pancreatic 
islet and liver hexokinase (A) (mU/mg protein) were not 
affected by glibenclamide treatment. Values shown are the 
means 2 S.E. for 3-18 experiments. 
Hexokinase activities from both tissues were slightly 
reduced by fasting (Fig. 1) but not affected by glibenclamide 
treatment in any of the experiments (Figs l-3). 
The inductive effect of glibenclamide treatment on gluco- 
kinase is not a direct effect of glibenclamide but rather an 
effect of the insulin released from the pancreatic B-cells in 
response to glibenclamide stimulation. This is proven by 
the fact that fed rats made diabetic (serum glucose con- 
centrations above 15 mM) by injection of alloxan (100 mg/ 
kg b. wt. four days before the experiment) presented liver 
glucokinase activities in the range of those observed in the 
liver from fasted non-diabetic rats [14] (4.7 2 0.4 mU/mg 
protein; N = 3). These low liver glucokinase activities from 
diabetic rats were not significantly raised by glibenclamide 
treatment (6.1 2 0.1 mU/mg protein N = 4) but nor- 
malized by insulin treatment (12.4 ? 1.3 mU/mg protein; 
N=6). 
Thus our experiments have shown that hypoglycemic 
sulfonylureas such as glibenclamide can maintain their long- 
term hypoglycemic action through induction of pancreatic 
islet and liver glucokinase by insulin. Induction of pan- 
creatic islet glucokinase keeps the glucose recognition sys- 
tem sensitive for the initiation of insulin secretion and 
biosynthesis by glucose stimulation. This induction of pan- 
creatic islet glucokinase by insulin augments the signal 
generating flux rate through the glycolytic pathway relative 
to the actual glucose concentration surrounding the pan- 
creatic B-cell. A sustained insulin secretory response of the 
pancreatic B-cell to absorptive and post-absorptive glucose 
keeps liver glucokinase in an induced state. This enables 
the liver to regulate the blood glucose concentration. Thus 
the induction of glucokinase in uiuo represents a link 
between the pancreatic and extrapancreatic effects of gli- 
benclamide and provides an explanation for the interaction 
between pancreatic islets and liver in the maintenance of 
glucose homeostasis [ 151. 
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Uptake and accumulation of gentamicin in the developing inner ear of the mouse 
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The sequences of both the bactericidal and the nephrotoxic 
actions of the aminoglycoside antibiotics include an energy- 
dependent uptake into the affected cells [l-3]. Whether an 
analogous step is also part of the ototoxic mechanism is not 
known. Pharmacokinetic studies relating to the cochlear 
actions of the aminoglycosides have only provided infor- 
mation on drug disposition in the fluids [4,5] and the tissues 
of the inner ear [6,7]. Questions of transport mechanisms 
or related issues such as whether the aminoglycosides enter 
the cells passively along, or actively against, a concentration 
gradient have not been addressed yet. Electrophysiological 
studies, however, have suggested that the ototoxic actions 
of gentamicin require an as yet undefined energy-dependent 
process [8], and a cellular uptake was postulated in a recent 
model of aminoglycoside ototoxicity [9]. 
To determine parameters of uptake, the drug con- 
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centrations in both the surrounding fluid and the tissue 
have to be known. Two problems arise with the inner ear. 
First, measurements of tissue volume (via wet weight) are 
difficult to obtain. Because of the small amount and the 
high surface to volume ratio of the tissues, adhering endo- 
lymphatic or perilymphatic fluid can produce large errors 
in the estimate of wet weight. Second, pharmacokinetic 
studies have so far been unable to determine whether 
serum, perilymph or endolymph, is the preferred route of 
drug access to the labyrinthine tissues. 
The present study minimizes these complications by 
measuring the uptake of gentamicin into the inner ear in 
organ culture. The embryonic inner ear is easy to manipu- 
late, will differentiate in culture [lo], and is susceptible to 
aminoglycosides (111. Drug concentrations in the culture 
medium can be defined and compared to those in the otic 
explants. 
Materials and methods 
Organ culture. Normal hybrid CBA/C57 mouse embryos 
were obtained by mating CBA-J and C57 mice (Jackson 
Laboratories, Bar Harbor, ME). The day at which a mucoid 
vaginal plug was found was designated as the first day of 
gestation. On gestational day 16, pregnant mice were killed 
by cervical dislocation, and their gravid uteri were placed 
in Dulbecco’s phosphate-buffered saline (PBS). Embryos 
were removed, and their developmental stages were 
assessed [12]. The embryonic inner ear with its associated 
cartilaginous otic capsule and ganglionic tissue was dis- 
sected and explanted to organ culture dishes, Care was 
taken to free the otic explants of any adhering middle ear 
mesenchyme. 
Each culture dish (Falcon, 35 x 10mm; Becton, Dick- 
inson & Co., Oxnard, CA) contained three otic explants 
in 2 ml of Neumann-Tytell medium (Gibco Laboratories, 
Grand Island. NY). suoulemented with 20% fetal calf 
serum and 25 pg ascorbic acid/ml. Explants were grown 
under 5% CO2 in air (95% relative humidity) at 36.5” for 
1, 3 or 5 days. When indicated, gentamicin was added at 
concentrations of 0.1 to approximately 20pg/ml culture 
medium. At the end of the culture period, explants were 
washed twice in PBS, blotted on filter paper, weighed, and 
pooled in sterile plastic tubes. Samples of culture medium 
were also withdrawn from each dish. Explants and medium 
were stored at -20” until assayed for their aminoglycoside 
levels. 
Assays. The otocysts were homogenized in 0.2M pot- 
assium phosphate, pH8.0, and protein was measured in 
the homogenates [13]. Gentamicin was determined in the 
supernatant fraction after centrifugation at 12,000g for 
10 min [7]. The radioimmunoassay (American Bioclinical, 
Portland, OR) was modified after Meulemans er al. [14] to 
increase sensitivity. 
Results and discussion 
Otic explants developed in organ culture without any 
gross pathology induced by gentamicin. The average gain 
in weight and protein content of the explants during culture 
was not affected significantly by the presence of the drug 
(13.5 pg increase in protein/explant from day 1 to day 5 for 
controls vs 12.7 pg at 10 pg gentamicin/ml of medium). 
Morphogenesis appeared normal with well-defined semi- 
circular ducts and a coiled cochlear duct (Fig. 1). It should 
be noted, however, that pathological changes in hair cells 
have been observed by transmission electron microscopy 
in explants cultured at gentamicin concentrations of 1 pg/ 
ml or greater [ 111, indicating that the developing inner ear 
is susceptible to damage by aminoglycosides. 
The uptake of gentamicin into the inner ear was depen- 
dent on both time and drug concentration in the medium 
(Fig. 2). Incubations without gentamicin served as controls 
for the specificity of the drug assay. It is interesting to 
note that the concentrations in the explants (0.1 to 1 ng 
Fig. 1. Otic explant of 16-day-old embryo after 5 days in 
vitro. The explant was grown in the presence of 1Opg 
gentamicin/ml of culture medium as described in Materials 
and Methods. Morphogenesis is normal with well-defined 
semicircular ducts (SCD) and a coiled cochlear duct (CD). 
Calibration bar = 100 pm. 
1 
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Fig. 2. Concentration- and time-dependency of gentamicin 
uptake. Otic explants were cultured for 1 (M) or 5 
(M) days at different gentamicin concentrations in 
the medium as described in Materials and Methods. Values 
are means + S.D. from three otocysts per condition, each 
analyzed in duplicate. Note that the gentamicin con- 
centration on the abscissa is displayed in logarithmic units. 
“C”, control incubation without gentamicin. 
gentamicin/mg protein) were comparable to those reported 
for neomycin and gentamicin in inner ear tissues of the 
adult guinea pig and the rat after in viuo treatment with 
aminoglycosides [6,7]. 
The significant finding of this study is the observation 
that otic explants accumulated gentamicin over con- 
centrations in the culture medium. Concentrations of genta- 
micin in the inner ear were determined assuming that 1 mg 
(wet weight) of tissue is equivalent to 1 yl of volume. Over 
the range of 0.1 to 17 pg drug/ml of medium, the ratios of 
concentrations in the explants to those in the medium were 
inversely proportional to the drug concentration. Genta- 
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Table 1. Accumulation of gentamicin in the inner ear 
Incubation Gentamicin concentration 
time Medium* Explant Ratiot 
(days) (&ml) 
1 0.12 1.10 9.2 
1 1.6 3.8 2.4 
1 17.0 11.6 0.7 
3 0.19 2.11 11.1 
5 0.09 1.50 16.7 
5 0.19 2.57 13.5 
5 2.1 8.5 4.0 
5 13.7 38.6 2.8 
Otic explants were cultured in two sets of independent 
experiments and analyzed as described in Materials and 
Methods. Both sets of experiments were incorporated into 
this table. In the first set, three explants were incubated 
per condition; in the second set, six explants each were 
incubated for 3 and 5 days at 0.19 peg gentamicin/ml 
medium. Otic explants were analyzed individually for their 
gentamicin and protein content (see Fig. 1 for gentamicin 
concentrations/mg protein and standard deviations of the 
first set). For the weight determination, the three otic 
explants that were cultured together per dish were weighed 
together at the end of the incubation. To obtain gentamicin 
concentrations/mg explant, total gentamicin for these 
explants was calculated and divided by their combined 
weight. 
* Concentration at the end of the culture period. There 
were no significant differences in drug concentrations 
between the beginning and the end of the incubation. 
Numbers are means of at least duplicate determinations 
(each within 10% of the mean). 
: Ratio of gentamicin concentrations in otic explants to 
those in the culture medium. 
micin concentrations were up to 16-fold higher in the otic 
explants (Table 1). 
The results clearly indicate that the uptake of gentamicin 
into the inner ear proceeds against a concentrationgradi- 
ent, suggesting an active (i.e. energy-dependent) transport. 
Although its characteristics have yet to be elucidated, the 
gentamicin uptake appears to obey Michaelis-Menten kin- 
etics. The 5-day time points (Lineweaver-Burk analysis, 
correlation coefficient, r2 = 0.98) yielded a K,,, of 1.9 PM. 
In remarkably good agreement, K,,, calculated from the l- 
day time points (r2 = 0.98) was 1.5 PM. The presence of a 
high-affinity uptake system for gentamicin in inner ear 
tissues has important implications for an understanding of 
the ototoxic actions of aminoglycoside antibiotics. 
In summary, the developing inner ear in culture took 
up gentamicin from the surrounding medium against a 
* To whom correspondence should be addressed. 
concentration gradient with an apparent K,,, of approxi- 
mately 1.7 yM. Inner ears of CBA/C57 hybrid mouse 
embryos were explanted at gestational day 16 and main- 
tained in organ culture for 1,3 or 5 days in media containing 
from 0 to 17 pg gentamicin/ml. Gentamicin concentrations 
in the otocysts increased with incubation time and exceeded 
the drug concentration in the medium up to ldfold. This 
is the first suggestion that tissues of the inner ear may 
actively transport aminoglycoside antibiotics by a high- 
affinity uptake system. 
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Ketoconazole hepatotoxicity: an in vitro model 
(Received 7 February 1985; accepted 24 January 1986) 
Ketoconazole is the newest in a series of imidazole-deriva- 
tive antifungal agents. It has a broad spectrum of activity 
against both superficial and systemic mycoses [l-3]. Keto- 
conazole is distinct from other antifungal imidazoles in 
clinical use. It is the only one that is absorbed in sufficient 
quantity to achieve therapeutic blood levels. Thus, it is 
effective when given orally [2,4]. It does not induce its own 
metabolism in uivo, nor that of other drugs in uitro [5]. 
Like other imidazoles, however, it inhibits the metabolism 
of some drugs in clinical situations [6,7]; recent reports 
have suggested that it does so by inhibiting the microsomal 
P-450 enzyme system (81. 
As clinical use of ketoconazole increased, reports of 
adverse hepatic reactions appeared [g-11]. There are two 
general categories of reactions. Asymptomatic elevations 
of hepatocellular enzymes occur in 5-10% of patients at 
